Loading...

Major Indexes

Financial Summary


Precipio Inc.

Precipio Inc. (PRPO)

$1.27
0.09 (+7.63%)
Buy
B+
Market Info
Financial Info
Financial Modelling
Symbol PRPO
Price 1.27$
Beta 3.54
Volume Avrg. 1.12M
Market Cap 0.02B
Shares (2019) 5,695.16K
Last Div 0
Dividend Yield -
DCF Unlevered -12.34 Strong Sell
DCF Levered -7.52 Strong Sell
ROE NaN%
ROA NaN%
Operating Margin -328.63% Strong Sell
Debt / Equity NaN%
P/E -
P/B -

Income Statement

Quarter data
Download PRPO income statement Download PRPO income statement Download PRPO income statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Earnings Per Share Diluted -0.04-0.06-0.22-0.13-2.30-2.01-2.78-0.35-7.16-0.92-2.33
Net Profit Margin -0.09-0.16-0.31-0.26-0.58-0.51-19.94-4.89-12.01-5.48-3.27
Weighted Average Shares Outstanding 49.1949.245.105.105.105.105.105.105.105.105.70
Revenue 22.0220.0531.9731.4827.5427.081.651.561.722.864.05
Weighted Average Shares Outstanding (Diluted) 49.1949.2469.4269.427.277.4912.3222.694.6421.625.70
Gross Profit 11.619.7618.4415.0112.509.72-0.29-0.200.290.230.22
Dividend per Share -----------
Operating Income -1.90-3.61-2.97-9.50-15.76-17.32-9.20-7.82-15.51-13.91-13.31
Gross Margin 0.530.490.580.480.450.36-0.17-0.130.170.080.05
Income Tax Expense 0.040.150.040.15-0.050.52----0.28-
EBIT Margin -0.05-0.14-0.03-0.23-0.47-0.56-5.27-4.85-7.47-4.42-3.01
Net Income -1.92-3.13-9.78-8.33-15.99-13.94-32.95-7.62-20.69-15.69-13.24
Cost of Revenue 10.4210.2813.5316.4715.0517.361.941.761.432.642.91
Earnings Before Tax Margin -0.09-0.15-0.30-0.26-0.58-0.50-6.13-5.31-12.01-5.58-3.29
EBIT -1.90-3.61-2.97-9.50-15.76-17.32-9.20-7.82-15.51-13.91-13.31
EBITDA -1.04-2.90-0.87-7.23-13.01-15.07-8.71-7.56-12.87-12.67-12.20
Profit Margin -0.09-0.16-0.31-0.26-0.58-0.51-19.94-4.89-12.01-5.48-3.27
Operating Expenses 13.5013.2421.4124.5128.2527.048.917.6115.8014.1411.21
Earnings Per Share Basic -0.04-0.06-0.22-0.13-2.30-2.01-2.78-0.35-7.16-0.92-2.33
Earnings before Tax -1.88-2.98-9.74-8.18-16.04-13.42-10.14-8.27-20.69-15.97-13.31
Interest Expense -0.00--------0.47

Balance Sheet Statement

Quarter data
Download PRPO balance shet statement Download PRPO balance sheet statement Download PRPO balance sheet statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Short-term debt -0.993.706.170.240.467.607.810.590.260.05
Other Assets --------0.020.030.54
Total current liabilities 4.108.2516.3316.538.6311.1216.9819.8210.0413.774.33
Cash and cash equivalents 5.643.454.954.501.631.610.440.110.420.380.85
Long-term debt 2.520.994.946.176.327.387.607.812.830.150.32
Cash and short-term investments 5.643.454.954.501.631.610.440.110.420.380.85
Total debt 4.5217.238.646.176.567.847.607.813.420.420.66
Inventories 3.553.343.865.093.963.000.050.020.160.200.18
Deferred revenue ---1.171.091.030.220.170.070.050.04
Goodwill and Intangible Assets -15.2414.4117.6816.1114.881.170.5625.1419.2916.66
Total non-current liabilities 2.761.836.191.117.839.780.350.203.010.270.32
Total non-current assets -15.2416.3620.0718.4416.571.530.7625.5219.8117.09
Total liabilities 4.3423.5322.5118.5218.8323.4517.6420.6114.2315.486.31
Total assets 14.4530.2733.5638.7930.2830.014.821.2627.2621.6119.51
Other comprehensive income 9.526.41153.01170.91179.49189.72200.44205.8844.4753.4711.87
Short-term investments ------1.990.03---
Property, Plant & Equipment Net --1.862.192.001.480.260.140.350.500.43
Net Debt -1.1213.783.691.674.936.237.157.703.000.04-0.19
Investments ------1.990.03---
Total shareholders equity 11.668.5011.0520.2711.456.55-12.82-19.3513.036.1213.21
Retained earnings (deficit) ---142.80-151.79-168.50-183.59-213.41-225.49-31.54-47.70-
Long-term investments -----------
Receivables 4.527.607.578.085.317.630.260.230.730.690.57
Payables 1.011.362.612.052.864.873.786.545.105.171.94
Total current assets 14.4515.0317.2018.7211.8413.433.280.491.741.791.88

Cash Flow Statement

Quarter data
Download PRPO cash flow statement Download PRPO cash flow statement Download PRPO cash flow statement
Year 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Investing Cash Flow -0.38-6.23-0.51-4.88-1.773.631.791.01-0.04-0.10-0.06
Free Cash Flow 0.92-1.91-0.01-11.09-9.08-13.83-12.58-3.57-6.83-6.85-9.20
Depreciation & Amortization 0.850.712.102.282.752.250.490.262.641.241.12
Net cash flow / Change in cash --1.49-0.45-2.87-0.02-1.17-0.330.37-0.04-
Effect of forex changes on cash --0.050.03-0.00-0.010.43----
Financing Cash Flow -5.761.7314.607.3710.078.992.217.106.819.66
Dividend payments --0.600.66-------
Stock-based compensation 0.20-0.011.010.730.460.940.610.050.050.530.67
Investment purchases ----8.99-------
Acquisitions and disposals -----------
Capital Expenditure 0.350.190.230.880.600.130.200.020.140.100.06
Operating Cash Flow 1.27-1.720.22-10.20-8.47-13.70-12.38-3.55-6.69-6.75-9.14

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) ----143-152-169-184-213-225-32-48
Net Income -2-3-10-8-16-14-33-8-21-16-13
Stock Dividends 23-134-1-1-13-4215-061
Dividend Paid --11-------
Retained Earnings ---143-152-169-184-213-225-32-48-

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE ---22210000
Annual Depreciation -0-02-1-1-1-1-000-0
Capital Expenditure 00011000000
Net PPE --222100000

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) --1514181615112519
New Purchases ----9-------
Intangible and Goodwill -151418161511251917

About


Mr. Ilan Danieli
Healthcare
Diagnostics & Research
NASDAQ Capital Market

Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; and HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test. It serves oncologists, hospitals, reference laboratories, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine and Harvard's Dana-Farber Cancer Institute. The company is based in New Haven, Connecticut.